AlphaTON Capital and Subsidiary Cyncado Therapeutics Pioneer Convergence of Digital Assets and Oncology Innovation: Exploring Tokenization Framework for Mesothelioma Program as it Advances Toward Q1 2026 First Patient Dosing
AlphaTON Capital (NASDAQ: ATON) and its oncology subsidiary Cyncado Therapeutics announced a non-binding LOI to evaluate tokenization of the economic rights for TT-4, an oral A2B receptor antagonist targeting mesothelioma. Cyncado is in final start-up preparations for TT-4 with first-patient dosing targeted for Q1 2026 under its existing FDA-cleared TT-10-101 protocol, followed by a mesothelioma-focused study at major U.S. cancer centers. Preclinical results cited include >90% tumor growth inhibition, 60% complete responses with anti-PD-1 combination, and >90-day survival in combination groups. The LOI is exploratory and non-binding; any tokenization would preserve traditional licensing and financing pathways and require board approval and regulatory clearance.
AlphaTON Capital (NASDAQ: ATON) e la sua sussidiaria oncologia Cyncado Therapeutics hanno annunciato una LOI non vincolante per valutare la tokenizzazione dei diritti economici per TT-4, un antagonista orale del recettore A2B che punta al mesotelioma. Cyncado è nelle fasi finali di preparazione allo start-up per TT-4 con la prima somministrazione al paziente prevista per il Q1 2026 secondo l'attuale protocollo TT-10-101 approvato dalla FDA, seguito da uno studio mirato al mesotelioma presso importanti centri oncologici statunitensi. I risultati preclinici citati includono >90% di inibizione della crescita tumorale, 60% di risposte complete con la combinazione anti-PD-1, e >90 giorni di sopravvivenza nei gruppi di combinazione. La LOI è esplorativa e non vincolante; qualsiasi tokenizzazione preserverebbe i tradizionali canali di licenza e finanziamento e richiederebbe l'approvazione del consiglio e l'autorizzazione regolatoria.
AlphaTON Capital (NASDAQ: ATON) y su filial oncológica Cyncado Therapeutics anunciaron una LOI no vinculante para evaluar la tokenización de los derechos económicos de TT-4, un antagonista oral del receptor A2B dirigido al mesotelioma. Cyncado se encuentra en las preparaciones finales de puesta en marcha para TT-4 con la dosificación al primer paciente prevista para el Q1 de 2026 según su protocolo TT-10-101 ya autorizado por la FDA, seguido por un estudio centrado en el mesotelioma en importantes centros oncológicos de EE. UU. Se citan resultados preclínicos: >90% de inhibición del crecimiento tumoral, 60% de respuestas completas con la combinación anti-PD-1 y >90 días de supervivencia en los grupos de combinación. La LOI es exploratoria y no vinculante; cualquier tokenización conservaría las rutas tradicionales de licencia y financiación y requeriría la aprobación de la junta y la autorización regulatoria.
AlphaTON Capital (나스닥: ATON) 와 그 암제학 자회사 Cyncado Therapeutics는 TT-4의 경제적 권리를 토큰화하는 것을 평가하기 위한 구속력 없는 LOI를 발표했습니다. TT-4는 mesothelioma를 표적으로 하는 구강용 A2B 수용체 길항제입니다. Cyncado는 첫 환자 투여가 2026년 1분기 목표로 FDA에서 승인된 TT-10-101 프로토콜에 따라 TT-4의 시작 준비를 마치고 있으며, 그 뒤로 미국 주요 암 센터에서 mesothelioma 중심 연구가 이어질 예정입니다. 인용된 전임상 결과로는 종양 성장 억제 >90%, 항-PD-1 병용에서 60%의 완전 반응, 병용군에서 >90일 생존 등이 있습니다. LOI는 탐색적이고 구속력이 없으며, 토큰화가 이루어지더라도 기존 면허 및 자금 조달 경로를 유지하고 이사회 승인 및 규제 승인이 필요합니다.
AlphaTON Capital (NASDAQ : ATON) et sa filiale oncologie Cyncado Therapeutics ont annoncé une LOI non contraignante visant à évaluer la tokenisation des droits économiques pour TT-4, un antagoniste oral du récepteur A2B ciblant le mesotheliome. Cyncado est en phase finale de préparation du démarrage pour TT-4 avec la première administration au patient prévue pour le Q1 2026 selon le protocole TT-10-101 déjà approuvé par la FDA, suivie d'une étude axée sur le mesotheliome dans d'importants centres oncologiques américains. Les résultats précliniques cités incluent >90 % d'inhibition de la croissance tumorale, 60 % de réponses complètes avec la combinaison anti-PD-1, et >90 jours de survie dans les groupes de combinaison. La LOI est exploratoire et non contraignante; toute tokenisation préserverait les voies traditionnelles de licence et de financement et nécessiterait l'approbation du conseil et l'autorisation réglementaire.
AlphaTON Capital (NASDAQ: ATON) und seine Onkologie-Tochtergesellschaft Cyncado Therapeutics gaben eine unverbindliche LOI bekannt, um die Tokenisierung der wirtschaftlichen Rechte für TT-4, einen oralen Antagonisten des A2B-Rezeptors, der auf Mesotheliom abzielt, zu evaluieren. Cyncado befindet sich in den abschließenden Start-up-Vorbereitungen für TT-4 mit erstem Patienteneinsatz geplant für Q1 2026 gemäß dem bereits von der FDA freigegebenen Protokoll TT-10-101, gefolgt von einer mesotheliomfokussierten Studie an führenden US-Krebszentren. Zu den zitierten präklinischen Ergebnissen gehören >90% Tumorwachstumshemmung, 60% komplette Antworten mit Anti-PD-1-Kombination und >90 Tage Überleben in den Kombinationsgruppen. Die LOI ist explorativ und unverbindlich; eine Tokenisierung würde traditionelle Lizenz- und Finanzierungskanäle bewahren und eine Vorstandsgenehmigung sowie regulatorische Zulassung erfordern.
AlphaTON Capital (ناسداك: ATON) وشركتها الفرعية في الأورام Cyncado Therapeutics أعلنوا عن LOI غير مُلزِم لتقييم توكنة الحقوق الاقتصادية لـ TT-4، وهو مضاد مستقبل A2B فموي يستهدف الورم البلاستيكي (المِسوتيلِيوم). Cyncado في المراحل النهائية من التحضير لبدء TT-4 مع تحديد جرعة أول مريض في الربع الأول من 2026 وفق البروتوكول TT-10-101 المعتمد أصلاً من FDA، يليه دراسة مركّزة على الورم البلّيني في مراكز سرطانية كبرى في الولايات المتحدة. النتائج قبل المخبرية المذكورة تشمل أكثر من 90% من تثبيط نمو الورم، و60% استجابات كاملة مع الجمع مع anti-PD-1، وأكثر من 90 يوماً للبقاء في مجموعات الجمع. LOI استكشافية وغير ملزمة؛ أي توكنيزيشن سيحافظ على مسارات الرخصة والتمويل التقليدية ويتطلب موافقة المجلس والاعتماد التنظيمي.
AlphaTON Capital (纳斯达克: ATON) 及其肿瘤学子公司 Cyncado Therapeutics 宣布了一项非约束性 LOI，以评估对 TT-4 的经济权益进行代币化，该药为靶向间皮瘤的口服 A2B 受体拮抗剂。Cyncado 正在为 TT-4 进行最终启动准备，按其现有 FDA 核准的 TT-10-101 模式，计划在2026年第一季度首次给药，随后在美国主要癌症中心开展以间皮瘤为焦点的研究。所引的前臨床结果包括肿瘤生长抑制率>90%、与抗 PD-1 组合的完全缓解率60%、以及组合组>90天的生存期。LOI 为探索性且非绑定性；任何代币化将保留传统的许可与融资路径，并需要董事会批准及监管批准。
- Non-binding LOI to explore tokenization of TT-4 economics
- Cyncado targeting first-patient dosing in Q1 2026 for TT-4
- Preclinical: >90% tumor growth inhibition in mesothelioma models
- Preclinical: 60% complete responses with anti-PD-1 combination
- LOI is exploratory and non-binding with no commercial terms finalized
- Any tokenization requires board approval and regulatory clearance
- Clinical efficacy in humans not yet demonstrated; only preclinical data reported
Insights
Non-binding token LOI plus a confirmed clinical start timeline for TT-4 creates conditional operational and financing optionality.
AlphaTON and its subsidiary Cyncado combine a preliminary tokenization LOI with a clinical program targeting first‑patient dosing in
The clinical data cited are preclinical and specific:
Key risks include the non‑binding nature of the LOI, the need for board and regulatory approvals, and the reliance on translation from preclinical efficacy to human safety and efficacy. Watch for confirmation of IND/IDE milestones, enrollment start and first‑patient dosing in
Landmark Initiative Positions AlphaTON at Forefront of Decentralized Science (DeSci) Movement, Leveraging TON Infrastructure to Accelerate Life-Saving Cancer Research
Dover, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) ("AlphaTON" or the "Company"), alongside its wholly owned oncology subsidiary Tarus Therapeutics, LLC (dba Cyncado Therapeutics) ("Cyncado"), today announced a groundbreaking non-binding letter of intent (LOI) to evaluate tokenization of single-indication economics for TT-4 in mesothelioma, representing a transformative step in merging institutional-grade digital asset infrastructure with breakthrough cancer therapeutics.
This pioneering initiative exemplifies AlphaTON's unique position as the only Nasdaq-listed company simultaneously operating a strategic TON token treasury and advancing potentially first-in-class immunotherapy assets. The Company is leveraging decentralized science (DeSci) principles and web3 infrastructure to reimagine how life-saving medical research is funded, accelerated, and brought to patients globally.
Bridging Two Frontiers: Digital Assets Meet Life-Saving Science
AlphaTON's strategic vision unites two high-impact domains previously operating in parallel: the Company's comprehensive TON ecosystem operations - including validator services, network staking, and Telegram-based application development serving over one billion users - with Cyncado's clinical-stage pipeline targeting immune checkpoint resistance in deadly cancers.
"We are witnessing the birth of a new paradigm in biomedical innovation," said Brittany Kaiser, Chief Executive Officer of AlphaTON Capital. "By thoughtfully integrating our digital asset capabilities with Cyncado's compelling oncology programs, we're not just exploring novel financing mechanisms, we're pioneering the future of decentralized science. This approach has the potential to democratize access to groundbreaking cancer research, accelerate development timelines, and create unprecedented alignment between global stakeholders and patient outcomes."
The mesothelioma tokenization initiative represents the first step in what could become a transformative model for funding and advancing therapeutic development through decentralized infrastructure, while preserving all traditional partnership, licensing, and exit pathways. Coupled with TON’s infinite sharding paradigm (ISP) data architecture, this new advancement not only has the opportunity to safeguard quality of life for patients, but also HIPAA-compliant data ownership and security for sensitive clinical on-chain data applications.
Clinical Momentum: TT-4 Advancing Toward Patients in Q1 2026
Cyncado has confirmed it is in final clinical start-up preparations for TT-4, an oral, ultra-selective A2B receptor antagonist, with first-patient dosing targeted for Q1 2026. The drug will initially enter a safety dose-escalation cohort enrolling solid tumor patients under Cyncado's existing FDA-cleared TT-10-101 (ADPORT-601) protocol, with a larger mesothelioma-focused study planned immediately thereafter at major U.S. cancer centers.
Mesothelioma, an aggressive cancer primarily caused by asbestos exposure, represents a significant unmet medical need with limited treatment options and poor prognosis. TT-4's preclinical data demonstrate compelling potential:
- >
90% tumor growth inhibition in murine mesothelioma models when combined with anti-PD1 antibody -
60% complete responses when combined with anti-PD-1 therapy - >90-day survival in combination treatment groups
- Mechanistic validation supports TT-4’s potential to fully neutralize adenosine-mediated immune suppression, enhance anti-tumor responses, and broaden the impact of immunotherapy in mesothelioma
- Superior single-agent activity compared to anti-PD-1 checkpoint inhibitors in head-to-head model comparisons
"The scientific and clinical community's response to our mesothelioma program has been extraordinarily positive," said Peter Molloy, Chief Executive Officer of Cyncado Therapeutics. "Key opinion leaders in the U.S. and internationally recognize the urgent need for new approaches in this devastating disease. We are in active discussions with leading non-U.S. investigators regarding additional mesothelioma studies that would complement our planned U.S. clinical program, potentially accelerating global development and patient access."
Decentralized Science: A New Model for Medical Innovation
The DeSci movement represents a fundamental reimagining of how scientific research is funded, conducted, and shared. By leveraging blockchain technology and tokenization, DeSci aims to:
- Democratize research funding by enabling global participation in supporting promising therapeutic programs
- Accelerate development timelines through efficient capital deployment and stakeholder alignment
- Enhance transparency in clinical development and data sharing
- Create direct value alignment between research supporters and therapeutic success
- Reduce traditional barriers to advancing innovative medicines to patients in need
AlphaTON's exploration of tokenizing mesothelioma program economics positions the Company at the vanguard of this movement, combining proven Nasdaq governance standards with cutting-edge decentralized infrastructure.
"This is about more than innovation in capital formation," Kaiser continued. "We're building bridges between Telegram's billion-user platform, the TON ecosystem's powerful infrastructure, and breakthrough cancer research that could save lives. Every element of AlphaTON's business model is designed to create synergies - our validator operations strengthen network security, our ecosystem investments drive utility and adoption, and now our therapeutic programs demonstrate how DeSci can accelerate the path from laboratory to patient."
Preserving Optionality, Maximizing Impact
The LOI is exploratory and non-binding, with no commercial terms or structures finalized. Critically, any potential tokenization framework is being designed to preserve, not replace, all traditional pathways for therapeutic development, including conventional partnerships, strategic licensing, acquisition opportunities, and institutional financing.
Any future transaction would require board approval, regulatory clearance, and full compliance with applicable securities laws and regulations. This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
About AlphaTON Capital Corp
AlphaTON Capital is a specialized digital asset treasury company focused on building and managing a strategic reserve of TON tokens and developing the Telegram ecosystem. The Company implements a comprehensive treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, AlphaTON Capital provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform while maintaining the governance standards and reporting transparency of a Nasdaq listed company. Led by Chief Executive Officer Brittany Kaiser, the Company's activities span network validation and staking operations, development of Telegram-based applications, and strategic investments in TON-based decentralized finance protocols, gaming platforms, and business applications. AlphaTON Capital Corp is incorporated in the British Virgin Islands and trades on Nasdaq under the ticker symbol “ATON”. AlphaTON Capital, through its legacy business, is also advancing potentially first-in-class therapies that target known checkpoint resistance pathways to potentially achieve durable treatment response and improve quality of life for patients. AlphaTON Capital actively engages in the drug development process and provides strategic counsel to guide development of novel immunotherapy assets and asset combinations.
About Cyncado Therapeutics
Tarus Therapeutics, LLC (dba Cyncado Therapeutics), a clinical stage, wholly owned subsidiary of AlphaTON Capital Corp, is developing potentially best-in-class small molecule adenosine receptor antagonists targeting A2A and A2B receptors to overcome immune suppression in oncology. The Company's lead program, TT-4, is an oral, ultra-selective A2B receptor antagonist with an initial focus on mesothelioma, advancing toward first-patient dosing in Q1 2026. Cyncado is also developing dual-antagonist strategies designed to achieve comprehensive blockade of adenosine-mediated immune evasion, potentially unlocking synergistic anti-tumor effects and durable patient responses.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements other than statements of historical fact, including statements regarding the Company's business strategy, plans and objectives, future operations, exploration of tokenization frameworks, clinical development timelines, potential DeSci applications, TON ecosystem growth, therapeutic development outcomes, regulatory approvals, financing activities, and statements preceded by, followed by, or including words such as "believe," "expects," "anticipates," "intends," "estimates," "will," "may," "plans," "potential," "targets," or similar expressions, are forward-looking statements.
These forward-looking statements are subject to substantial risks and uncertainties, including but not limited to: risks that tokenization or DeSci frameworks may not be pursued or successfully implemented; uncertainty regarding the Company’s and Cyncado’s ability to enter into definitive agreements on reasonable terms; uncertainty regarding clinical trial outcomes and regulatory approvals; uncertainty of the Company's investment in TON and digital assets; regulatory and legal risks associated with digital assets and tokenization; risks related to Telegram's platform and the TON ecosystem; market volatility; competitive risks in both digital assets and therapeutics development; ability to attract and retain key personnel; the Company’s ability to satisfy its debt service obligations and covenant compliance; macroeconomic conditions; and other factors described in "Item 3 – Key Information-Risk Factors" in the Company's Annual Report on Form 20-F for the year ended March 31, 2025, and subsequent reports filed with the Securities and Exchange Commission.
Although the Company believes the expectations reflected in these forward-looking statements are reasonable, actual results may differ materially. The Company undertakes no obligation to update publicly or revise any forward-looking statements, except as required by law.
Contact Information
Investor Relations:
AlphaTON Capital Corp
AlphaTON@icrinc.com
(203) 682-8200
Media Inquiries:
Richard Laermer
RLM PR
AlphaTON@rlmpr.com
(212) 741-5106 X 216
Richard Laermer RLM PR AlphaTON (at) rlmpr.com
FAQ
What did AlphaTON (ATON) announce about tokenizing its mesothelioma program on October 8, 2025?
When is Cyncado's TT-4 first-patient dosing expected for ATON investors?
What preclinical results did ATON report for TT-4 in mesothelioma models?
Does the ATON tokenization LOI replace traditional financing or licensing options?
Is the ATON tokenization plan finalized and immediately investable?
What regulatory or corporate approvals are required before ATON can tokenize TT-4 economics?
